Literature DB >> 15812402

Visible endoscopic and histologic changes in the cardia, before and after complete Barrett's esophagus ablation.

Allan P Weston1, Prateek Sharma, Sushanta Banerjee, Daniela Mitreva, Sharad Mathur.   

Abstract

BACKGROUND: Adverse events associated with the thermal ablation of Barrett's esophagus (BE) include the generation of gastric mucosa buried beneath the neosquamous regrowth, and unrecognized development and growth of adenocarcinomas. No reports exist regarding the endoscopic appearance and histology of the cardia before and after BE ablation. The aim of our study was to assess the relative frequency of the occurrence of visible endoscopic and histologic changes in the cardia, before and after complete BE ablation.
METHODS: A subset analysis of patients with uncomplicated BE, BE with dysplasia, or early carcinoma, who had been enrolled into one of 4 ongoing prospective studies of mucosal ablation, was examined. Eighty-two patients were identified who entered a BE ablation study, with 75 of these completing BE mucosal ablation. Cardia biopsy specimens were taken in all patients before ablation and serially after BE ablation. Cardia histology was graded by using the modified Sydney System for gastritis.
RESULTS: Before ablation, cardia nodules were noted in 3, cardia intestinal metaplasia (IM) in 7 (8.5%), and none harbored cardia dysplasia. Postablation surveillance ranged from 3 to 75 months (mean 31.1 months [19.5]). Six subjects (8%) developed cardia nodules during surveillance; cardia IM was found in 21(28%), with 17 of these being a new finding (incidence of 25%). Cardia low-grade dysplasia incidence was 1.3% and high-grade dysplasia was 4% after BE ablation.
CONCLUSIONS: The pathophysiology of the abnormal cardia histology and the endoscopic lesions (nodules) is unclear, but endoscopic surveillance of not only the neosquamous epithelium but also the cardia should be considered after ablation, especially in those high-grade dysplasia and early adenocarcinoma BE patients.

Entities:  

Mesh:

Year:  2005        PMID: 15812402     DOI: 10.1016/s0016-5107(05)00131-8

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  6 in total

1.  Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves.

Authors:  Gary W Falk
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

2.  Prevalence and Incidence of Intestinal Metaplasia and Dysplasia of Gastric Cardia in Patients With Barrett's Esophagus After Endoscopic Therapy.

Authors:  Swathi Eluri; Athidi G Earasi; Susan E Moist; Evan S Dellon; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-08       Impact factor: 11.382

Review 3.  Endoscopic management of Barrett esophagus.

Authors:  Aparna Repaka; Amitabh Chak
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-09-06       Impact factor: 46.802

4.  Neoplastic Barrett's oesophagus and long-term follow-up after endoscopic therapy: complete histological eradication of Barrett associated with high-grade dysplasia significantly decreases neoplasia relapse.

Authors:  Fabrice Caillol; Sebastien Godat; Aurelie Autret; Erwan Bories; Christian Pesenti; Jean Phillippe Ratone; Flora Poizat; Jerome Guiramand; Jean Robert Delpero; Marc Giovannini
Journal:  Surg Endosc       Date:  2016-04-29       Impact factor: 4.584

5.  Barrett's esophagus: review of diagnosis and treatment.

Authors:  Raja Shekhar Sappati Biyyani; Amithab Chak
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-30

6.  Current Controversies in Radiofrequency Ablation Therapy for Barrett's Esophagus.

Authors:  Kamar Belghazi; Ilaria Cipollone; Jacques J G H M Bergman; Roos E Pouw
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.